Article Text

Download PDFPDF

60 Comprehensive genome-wide analysis of non-invasive test data allows accurate cancer prediction: a retrospective analysis of over 85.000 pregnancies
  1. L Lenaerts1,
  2. N Brison2,
  3. C Maggen1,
  4. L Vancoillie2,
  5. H Che3,
  6. P Vandenberghe4,
  7. D Dierickx4,
  8. L Michaux2,
  9. B Dewaele2,
  10. P Neven5,
  11. G Floris6,
  12. T Jatsenko3,
  13. K Van Calsteren5,
  14. V Vandecaveye7,
  15. L Dehaspe8,
  16. K Devriendt2,
  17. E Legius2,
  18. K Van Den Bogaert2,
  19. J Vermeesch3 and
  20. F Amant1
  1. 1Catholic University Leuven, Oncology, Belgium
  2. 2University Hospitals Leuven, Center for Human Genetics, Belgium
  3. 3Catholic University Leuven, Human Genetics, Belgium
  4. 4University Hospitals Leuven, Hematology, Belgium
  5. 5University Hospitals Leuven, Gynaecology and Obstetrics
  6. 6University Hospitals Leuven, Pathology, Belgium
  7. 7University Hospitals Leuven, Radiology, Belgium
  8. 8Catholic University Leuven, Genomics Core facility, Belgium


Introduction/Background*Implausible false positive results in non-invasive prenatal testing (NIPT) have been occasionally associated with the detection of occult maternal malignancies. Hence, there is a need for approaches allowing accurate prediction of whether the NIPT result is pointing to an underlying malignancy, as well as for organized programs ensuring efficient downstream clinical management of these cases.

Methodology Using a large data set of 88,294 NIPT performed in our University Hospital Leuven, we retrospectively evaluated the positive predictive value (PPV) of our NIPT approach for cancer detection. In this approach, whole-genome cell-free DNA (cfDNA) data from NIPT were scrutinized for the presence of (sub)chromosomal copy number alterations (CNAs) predictive for a malignancy, using an unbiased NIPT analysis pipeline coined GIPSeq. For suspected cases, the presence of a maternal cancer was evaluated via subsequent multidisciplinary clinical follow-up examinations. The cancer-specificity of the identified CNAs in cfDNA was assessed through genetic analyses of a tumour biopsy.

Result(s)*Fifteen women without a cancer history were identified with a GIPSeq result suggestive of a malignant process. Their cfDNA profiles showed either genome-wide aberrations or a single trisomy 8. Upon clinical examinations, a solid or hematological cancer was identified in 4 and 7 cases, respectively. Three women were identified as having a clonal mosaicism. For one case no underlying condition was found. These numbers add to a PPV of 73%. Based on this experience, a novel multidisciplinary care path for efficient clinical management of these cases was presented.

Conclusion*The here presented approach for analysing NIPT results has an unparalleled high PPV, yet unknown sensitivity, for detecting asymptomatic malignancies upon routine NIPT. Given the complexity of diagnosing a pregnant woman with cancer, clinical follow-up should occur in a well-designed multidisciplinary setting, such as via the novel care model that we presented here.

These findings have now been accepted for publication in eClinicalMedicine (online journal of The Lancet group), showing the importance of these data.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.